433
Views
9
CrossRef citations to date
0
Altmetric
Reviews

Paroxetine mesylate: comparable to paroxetine hydrochloride?

, MD PhD, , , , &
Pages 185-193 | Published online: 21 Jan 2010

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Sara Gibiino & Alessandro Serretti. (2012) Paroxetine for the treatment of depression: a critical update. Expert Opinion on Pharmacotherapy 13:3, pages 421-431.
Read now

Articles from other publishers (8)

Chandani T. Muleva & Sonali S. Bharate. (2023) Halide counterions in FDA-approved pharmaceutical salts. Journal of Drug Delivery Science and Technology 89, pages 104999.
Crossref
Sonali S. Bharate. (2021) Modulation of biopharmaceutical properties of drugs using sulfonate counterions: A critical analysis of FDA-approved pharmaceutical salts. Journal of Drug Delivery Science and Technology 66, pages 102913.
Crossref
Sonali S. Bharate. (2021) Modulation of biopharmaceutical properties of acidic drugs using cationic counterions: A critical analysis of FDA-approved pharmaceutical salts. International Journal of Pharmaceutics 607, pages 120993.
Crossref
Mingming Li, Jian Cai, Ping Zhang, Chunhua Fei & Feng Xu. (2017) Drug Brand Response and Its Impact on Compliance and Efficacy in Depression Patients. Frontiers in Pharmacology 7.
Crossref
D Wei, Y Chen, C Wu, Q Wu, L Yao, Q Wang, XQ Wang & KH Yang. (2016) Effect and safety of paroxetine for vasomotor symptoms: systematic review and meta-analysis. BJOG: An International Journal of Obstetrics & Gynaecology 123:11, pages 1735-1743.
Crossref
Hoo Rim Song, Won-Myong Bahk, Young Sup Woo, Jong-Hyun Jeong, Young-Joon Kwon, Jeong Seok Seo, Won Kim, Moon-Doo Kim, Young-Chul Shin, Sang-Yeol Lee & Kyung Joon Min. (2015) Efficacy and Tolerability of Generic Mirtazapine (Mirtax) for Major Depressive Disorder: Multicenter, Open-label, Uncontrolled, Prospective Study. Clinical Psychopharmacology and Neuroscience 13:2, pages 144-149.
Crossref
Adrian S Dobs. (2013) A little better than placebo is still better than nothing. Nature Medicine 19:8, pages 962-962.
Crossref
M. Cristina Castelli, Sailaja Bhaskar & Joel Lippman. (2013) Pharmacokinetic Properties of Once-Daily Oral Low-Dose Mesylate Salt of Paroxetine (LDMP 7.5 mg) Following Single and Multiple Doses in Healthy Postmenopausal Women. Clinical Therapeutics 35:6, pages 862-869.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.